Leadership

  • Joel Lewis, CEO and President of Galectin Therapeutics

    Joel Lewis

    Chief Executive Officer (CEO) and President

    Joel Lewis is Chief Executive Officer (CEO) and President of Galectin Therapeutics. In this position, Mr. Lewis sets corporate strategy and oversees operations, most importantly Galectin’s global NASH-RX adaptively-designed trial for the prevention of varices in NASH cirrhosis patients using its proprietary galectin-3 inhibiting compound, belapectin (GR-MD-02). Mr. Lewis has served on the Board of Directors for Galectin Therapeutics since 2017. Mr. Lewis is a financial executive with over 25 years of experience, who began his career in public accounting in 1992. From 2007 through 2019, Mr. Lewis acted as the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies). Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition, and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.

    • Pol F. Boudes, M.D.

      Pol F. Boudes, M.D.

      Chief Medical Officer

      Dr. Boudes has more than 25 years of experience in clinical drug development in immunology, endocrine, metabolic, orphan, and liver-related diseases, and he has contributed to the approval of multiple drugs, both in the US and globally, across a variety of therapeutic indications. Before joining Galectin Therapeutics, Dr. Boudes was the chief medical officer at CymaBay Therapeutics -- where he worked on the company’s proprietary NASH compound and was instrumental in inventing and launching programs in rare liver diseases. Prior to CymaBay, Dr. Boudes was CMO at Amicus Therapeutics, a company focusing on rare lysosomal storage disorders. His prior positions include clinical development at Bayer HealthCare Pharmaceuticals, Wyeth Research, Hoffman-La Roche, and Pasteur Merieux.

      A dual citizen of the U.S. and France, Dr. Boudes earned his MD at the University of Marseilles, France. He completed his internship and residency in Marseilles and Paris, was an assistant professor of medicine at the University of Paris, and also participated in multiple clinical research programs as an investigator. He is certified by the Educational Commission for Foreign Medical Graduates (US) and board-specialized in endocrinology and metabolic diseases, internal medicine, as well as in geriatric diseases (Paris).

      Dr. Boudes holds several records of invention and has contributed to multiple peer-reviewed publications, notably on improving the clinical development process, and has served on the editorial review board for La Revue Prescrire -- a leading European Drug Therapeutic Bulletin -- as well as several scientific advisory boards for drug development. He is a member of several professional organizations, including the American Association for the Study of Liver Disease, the European Association for the Study of Liver (Geneva, Switzerland), the American Diabetes Association, the Royal Society of Medicine (London, U.K.), and the American Medical Association.

      • Jack Callicutt

        Jack W. Callicutt, CPA

        Chief Financial Officer

        Mr. Callicutt has over 28 years of public and private company experience including more than a decade of audit, tax and SEC registrant experience with a major accounting firm. He was most recently chief financial officer for REACH Health, Inc., a telemedicine firm, where he completed a $4 million private placement. Previous positions include chief financial officer of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include chief financial officer roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly-traded biopharmaceutical company. Mr. Callicutt is a certified public accountant and graduated cum laude with a B.B.A. degree in accounting and computer science from Delta State University.

        • Ezra R. Lowe, Ph.D.

          Ezra R. Lowe, Ph.D.

          Executive Director, Clinical and Preclinical Pharmacology

          Ezra Lowe brings his depth of experience in clinical pharmacology, drug metabolism, and pharmacokinetics to his role as Executive Director, Clinical and Preclinical Pharmacology at Galectin Therapeutics. He has a broad base of experience working with various drug formats across diverse array of therapeutic areas. Prior to joining Galectin Therapeutics, Ezra was Senior Director, Clinical Pharmacology in Global R&D with the Bausch Health Companies, where he was responsible for the execution of clinical pharmacology strategy across all companies of Bausch Health, including Salix Pharmaceuticals, Bausch + Lomb, and Ortho Dermatologics. Before that, he held Clinical and Nonclinical Pharmacology positions at Salix Pharmaceuticals, Bausch +Lomb, and Valeant Pharmaceuticals International, Inc. and spent time as Lead Scientist in Biotransformation and Toxicology at The Dow Chemical Company.

          In the course of his career, he has completed 10 different global drug approvals, and he was twice awarded the Bausch Health CEO award.

          Ezra holds a B.A. in Chemistry from Colgate University and a Ph.D. in Pharmacology from the University of Michigan. He is also an alumnus of the McKinsey Black Executive Leadership Program.

          • Dakshina Reddy headshot

            Dakshina Reddy

            Executive Director, Drug Regulatory Affairs

            Dakshina Reddy is a regulatory professional with over 22 years’ experience in drug regulatory affairs and clinical research. He has expertise in global regulatory strategy, drug development and regulatory life-cycle management. He has experience working with leading regulatory authorities, including the FDA, EMA, PMDA, Health Canada, as well emerging regulatory authorities in emerging/developing markets.

            Prior to joining Galectin Therapeutics, Dakshina was a Global Program Regulatory Director at Novartis Pharmaceuticals. Here he held various positions of increasing responsibility where he contributed towards growing and developing regulatory strategy, establishing teams, leading regulatory programs for expedited review and market approval as well as shaping regulatory markets that enabled increased access. He led and achieved multiple approvals in the U.S., E.U., Japan, Canada, Brazil and Mexico.  Before that he held regulatory positions at Amgen, AstraZeneca and Merck KGaA.

            In his career, he has worked across a wide range of therapeutic disciplines that included cardiovascular, metabolism, respiratory, neuroscience, oncology, immunology and HIV.

            Dakshina holds a degree in Pharmacy from Rhodes University, South Africa, and a Master of Science degree in Medicine from the University of the Witwatersrand, South Africa. He continues to be a member of several professional regulatory organizations.

            • Portrait photo of Marla Mills-Wilson

              Marla Mills-Wilson

              Executive Director, Clinical Operations

              Marla Mills-Wilson is a 24+ year clinical research veteran who brings to Galectin Therapeutics a deep experience in not only program management but also project management, study operations, site management and progression across Phase I to IV in a variety of therapeutic indications, including liver-related diseases, oncology, ophthalmology, and vaccines. Prior to joining Galectin Therapeutics,she spent the previous four years working in the rare liver disease space. She partnered and consulted with CymaBay Therapeutics to lead its global phase III Primary Biliary Cirrhosis program. Preceding CymaBay, Marla collaborated with Intercept Pharmaceuticals, where she was responsible for leading its global phase III fibrosis due to NASH study. Prior positions include serving as Director at INNO Clinical Outcomes, clinical operations management and oversight at Novella, Jubilant Clinsys, Inspire Pharmaceuticals, Glaxo Wellcome and Parexel – working cross functionally in an assortment of roles.

              Marla is named as a contributor on multiple ophthalmology manuscripts and posters. She also is a tremendous advocate of process improvement and is lean Six Sigma certified. She holds a B.S. from the University of Tennessee at Chattanooga and continues to be a member of several professional clinical research organizations.

              • Harold Shelvin

                Harold H. Shlevin, Ph.D.

                Consultant, Director and former Chief Executive Officer

                Dr. Shlevin is the retired former chief executive officer (CEO) and president of Galectin Therapeutics, now working with the Company on a consulting basis to help guide the Company’s ongoing Phase 2b/3 NASH-RX clinical trial. He is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics, and vaccines. Before joining Galectin Therapeutics as chief operating officer (COO) in 2012 and assuming the role of CEO and president in 2018, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US; co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, president and chief executive officer of Tikvah Therapeutics, a company focused on clinical development of therapeutics for treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Therapeutics Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics. Dr. Shlevin earned his B.A. from Boston University and M.S. and Ph.D. in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as assistant professor of pharmacology and physiology. He is a member of scientific and business societies including the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents.